EP1811024A1 — Oligo double-stranded rna and medicinal composition
Assigned to Nippon Shinyaku Co Ltd · Expires 2007-07-25 · 19y expired
What this patent protects
It is intended to provide an double-stranded RNA oligonucleotide inhibiting the replication of HCV and a medicinal composition containing this double-stranded RNA oligonucleotide for treating and/or preventing a disease induced by infection with HCV. The present invention relates…
USPTO Abstract
It is intended to provide an double-stranded RNA oligonucleotide inhibiting the replication of HCV and a medicinal composition containing this double-stranded RNA oligonucleotide for treating and/or preventing a disease induced by infection with HCV. The present invention relates to a double-stranded RNA oligonucleotide inhibiting the replication of HCV which is characterized by having a double-stranded portion comprising a pair of RNAs, SEQ ID NO.3 and SEQ ID NO.4 without the two deoxythymidine monophosphate (hereinafter referred to as "dT") nucleotides of at the respective 3'-termini, or a pair of RNAs, SEQ ID NO.2 and SEQ ID NO.5, without the two dT nucleotides at the respective 3'-terminals; and a medicinal composition containing this double-stranded RNA oligonucleotide together with a suitable carrier.
Drugs covered by this patent
- Viltepso (VILTOLARSEN) · Nippon Shinyaku
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.